文献速递免疫规划传染病防控与疫情报告

多抗原嵌合PvCSP-MSP119疫苗诱导针对间日疟原虫不同生活史阶段的强体液免疫应答

A multi-antigen chimeric PvCSP-MSP119 vaccine induces robust humoral responses against distinct stages of Plasmodium vivax.
PubMed 文献 · Vaccine · 2026-10-02

间日疟原虫是非洲以外疟疾的主要病因,亟需有效疫苗。本研究在小鼠中评估靶向红外期和红内期的单价抗原与新型嵌合蛋白PvCSP-MSP119的免疫原性。嵌合蛋白与联合抗原均诱导针对PvCSP和PvMSP119的IgG应答,蛋白初免-腺病毒加强策略诱导的IgG滴度最高,支持其作为多阶段疟疾疫苗候选进一步开发。

要点

  • 嵌合蛋白PvCSP-MSP119保留关键抗原表位,具良好免疫原性。
  • 蛋白初免后腺病毒加强诱导抗PvCSP和PvMSP119最高IgG滴度。
  • 嵌合蛋白在同源和异源方案中均诱导升高IgG1/IgG2c比值。

核心结论

  • PvCSP-MSP119嵌合蛋白具有高度免疫原性,能诱导针对间日疟原虫不同生活史阶段的免疫应答,支持其作为多阶段疟疾疫苗候选进一步开发。

研究设计与样本

  • 在C57BL/6小鼠中评估同源(蛋白/蛋白/蛋白)和异源(蛋白/腺病毒或腺病毒/蛋白)初免-加强方案,比较嵌合蛋白与单独/联合抗原及表达PvCSP(AdC68-PvCSP)或PvMSP119(AdHu5-PvMSP119)的复制缺陷腺病毒载体。

主要发现

  • 同源免疫嵌合蛋白或联合抗原均诱导针对PvCSP和PvMSP119的强IgG应答,但嵌合蛋白组抗PvMSP119滴度较低。
  • 异源策略中,蛋白初免后腺病毒加强针对两种抗原诱导的IgG滴度最高。
  • 嵌合蛋白在同源和异源方案中均一致诱导升高的IgG1/IgG2c比值。
  • 骨髓中抗原特异性抗体分泌细胞频率与观察到的体液应答密切平行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasmodium vivax is the leading cause of malaria outside Africa, highlighting the need for an effective vaccine. However, the development of vaccines against this parasite remains challenging because of its complex life cycle and antigenic diversity. In this study, we evaluated vaccine formulations targeting both the pre-erythrocytic and erythrocytic stages of P. vivax using either individual antigens or a novel chimeric protein. The chimeric construct combined the C-terminal region and variant repeat domains of the P. vivax circumsporozoite protein (PvCSP) with the 19-kDa C-terminal fragment of merozoite surface protein 1 (PvMSP119). Structural predictions indicated that the PvCSP region was predominantly disordered, whereas the PvMSP119 domain displayed a more ordered conformation, supporting the preservation of key antigenic features within the fusion protein. We also evaluated recombinant replication-defective adenoviral vectors expressing PvCSP (AdC68-PvCSP) or PvMSP119 (AdHu5-PvMSP119). Homologous (protein/protein/protein) and heterologous (protein/adenovirus or adenovirus/protein) prime-boost regimens were assessed in C57BL/6 mice. Homologous immunization with either the chimeric protein or coadministered antigens induced robust IgG responses against PvCSP and PvMSP119, although anti-PvMSP119 titers were lower in mice receiving the chimeric construct. Among heterologous strategies, protein priming followed by adenoviral boosting elicited the highest IgG titers against both antigens. The chimeric protein consistently induced elevated IgG1/IgG2c ratios under both homologous and heterologous regimens. Furthermore, the frequency of antigen-specific antibody-secreting cells in the bone marrow closely paralleled the observed humoral responses. Collectively, these findings demonstrate that the PvCSP-MSP119 chimeric protein is highly immunogenic and capable of inducing immune responses against distinct stages of the P. vivax life cycle, supporting its further development as a multistage malaria vaccine candidate.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Diniz LLCL, Santos DO, Maffetano CV, et al. A multi-antigen chimeric PvCSP-MSP119 vaccine induces robust humoral responses against distinct stages of Plasmodium vivax. Vaccine. 2026. PMID: 42826687. doi:10.1016/j.vaccine.2026.129197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。